New drug cocktail targets Hard-to-Treat sarcomas
NCT ID NCT07457775
First seen Mar 19, 2026 · Last updated May 07, 2026 · Updated 8 times
Summary
This study tests a combination of three drugs (liposomal irinotecan, temozolomide, and bevacizumab) in 24 people with advanced soft tissue sarcoma that has come back or not responded to prior treatment. The goal is to see if the combo can slow tumor growth and how safe it is. Participants must have had at least one prior therapy and have measurable tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA (EXCLUDING GIST) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
2nd Affiliated Hospital, School of Medicine
Hangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.